2024
Insulin Resistance in Type 2 Diabetes
Roden M, Petersen K, Shulman G. Insulin Resistance in Type 2 Diabetes. 2024, 238-249. DOI: 10.1002/9781119697473.ch17.Peer-Reviewed Original Research
2023
1569-P: Lysophosphatidic Acid Mediates Inflammation in Liver and White Adipose Tissue in a Rat Model of 1-acyl-sn-glycerol-3-phosphate Acyltransferase 2 Deficiency
SAKUMA I, GASPAR R, LUUKKONEN P, KAHN M, MURRAY S, SAMUEL V, PETERSEN K, SHULMAN G. 1569-P: Lysophosphatidic Acid Mediates Inflammation in Liver and White Adipose Tissue in a Rat Model of 1-acyl-sn-glycerol-3-phosphate Acyltransferase 2 Deficiency. Diabetes 2023, 72 DOI: 10.2337/db23-1569-p.Peer-Reviewed Original ResearchWhite adipose tissueControlled-release mitochondrial protonophoreCongenital generalized lipodystrophyAGPAT2 deficiencyHepatic inflammationASO treatmentAdipose tissueLysophosphatidic acidAdult male SD ratsAntisense oligonucleotideMale SD ratsNovel therapeutic targetNovo NordiskCRMP treatmentFortress BiotechWAT inflammationDohme Corp.SD ratsRat modelAGPAT2 geneGeneralized lipodystrophyInflammationTherapeutic targetIonis PharmaceuticalsDeficient animals
2016
Insulin Resistance in Type 2 Diabetes
Roden M, Petersen K, Shulman G. Insulin Resistance in Type 2 Diabetes. 2016, 174-186. DOI: 10.1002/9781118924853.ch13.Peer-Reviewed Original ResearchType 2 diabetesNon-alcoholic fatty liver diseaseInsulin resistanceInflammatory pathwaysAdipose tissueHepatic mitochondrial oxidative capacityLipid-mediated insulin resistanceFatty liver diseaseImpaired glucose toleranceDiabetes-related complicationsEctopic lipid accumulationΒ-cell dysfunctionFatty acid availabilityAction of insulinMitochondrial oxidative capacityAtherogenic dyslipidemiaMultiple deleterious effectsGlucose toleranceLiver diseaseCarbohydrate ingestionEctopic storagePostprandial hyperglycemiaSystemic abnormalitiesInhibits lipolysisFree fatty acids